Document is current

Article History

Received: 14 January 2022

Accepted: 23 March 2022

First Online: 7 May 2022

Declarations

:

: The plasmaMATCH trial was approved by the South Central - Oxford C Research Ethics Committee (REC reference: 16/SC/0271). All participants provided consent to take part in the research and for the trial results to be published.

: N/A.

: CS, SK, LM, NCT, AR, KW, SM, SF, LSK and JMB report grants from Cancer Research UK, grants and non-financial support in the form of study drug provision from AstraZeneca and Puma Biotechnology and non-financial support in the form of ctDNA sequencing from Guardant Health and provision of reagents from BioRad during the conduct of the study.NCT also reports grants and personal fees from AstraZeneca, Pfizer and Roche/Genentech; personal fees from Bristol-Myers Squibb, Lilly, MSD, Novartis, Bicycle Therapeutics, Taiiho, Zeno Pharmaceuticals and Repare Therapeutics; and grants from BioRad, Clovis, Merck Sharpe & Dohme and Guardant Health outside the submitted work.AR also reports honoraria from AstraZeneca for advisory boards and educational activities and personal fees from Roche Products Limited, Pfizer, Novartis, Lilly and MSD outside the submitted work.JMB also reports grants and non-financial support from AstraZeneca, Novartis, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Roche and Clovis Oncology and grants from Medivation outside the submitted work.